Terms: = Liver cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Treatment
16743 results:
1. Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization.
Zhao K; Son S; Karimi A; Marinelli B; Erinjeri JP; Alexander ES; Sotirchos VS; Harding JJ; Soares KC; Ziv E; Covey A; Sofocleous CT; Yarmohammadi H
Curr Oncol; 2024 May; 31(5):2650-2661. PubMed ID: 38785481
[TBL] [Abstract] [Full Text] [Related]
2. Borax affects cellular viability by inducing ER stress in hepatocellular carcinoma cells by targeting SLC12A5.
Hacioglu C; Oral D
J Cell Mol Med; 2024 May; 28(10):e18380. PubMed ID: 38780503
[TBL] [Abstract] [Full Text] [Related]
3. ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells.
Wu P; Wang X; Yin M; Zhu W; Chen Z; Zhang Y; Jiang Z; Shi L; Zhu Q
Int J Nanomedicine; 2024; 19():4465-4493. PubMed ID: 38779103
[TBL] [Abstract] [Full Text] [Related]
4. Epidemiological, Diagnostic and Therapeutic Aspects of Hepatocellular Carcinoma in Morocco: A Case Series and Review of Literature.
Zouaki I; Aiterrami A; Samlani Z; Oubaha S; Krati K
Gulf J Oncolog; 2024 May; 1(45):75-90. PubMed ID: 38774936
[TBL] [Abstract] [Full Text] [Related]
5. Role of peritumoral tissue analysis in predicting characteristics of hepatocellular carcinoma using ultrasound-based radiomics.
Qian H; Huang Y; Xu L; Fu H; Lu B
Sci Rep; 2024 May; 14(1):11538. PubMed ID: 38773179
[TBL] [Abstract] [Full Text] [Related]
6. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
[TBL] [Abstract] [Full Text] [Related]
7. Angiotensin-converting enzyme 2 and AMPK/mTOR pathway in the treatment of liver fibrosis: Should we consider further implications?
Barone M
World J Gastroenterol; 2024 May; 30(18):2391-2396. PubMed ID: 38764773
[TBL] [Abstract] [Full Text] [Related]
8. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
Wang X; Yang Y
Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
[TBL] [Abstract] [Full Text] [Related]
9. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
10. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
11. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
12. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
13. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
Xiao Y; Deng W; Luo L; Zhu G; Xie J; Liu Y; Wan R; Wen W; Hu Z; Shan R
BMC Cancer; 2024 May; 24(1):588. PubMed ID: 38745113
[TBL] [Abstract] [Full Text] [Related]
14. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
[TBL] [Abstract] [Full Text] [Related]
15. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
[TBL] [Abstract] [Full Text] [Related]
16. Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
Liu K; Li Q; Lu X; Fan X; Yang Y; Xie W; Kang J; Sun S; Zhao J
Pharm Biol; 2024 Dec; 62(1):404-422. PubMed ID: 38739082
[TBL] [Abstract] [Full Text] [Related]
17. [Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study].
Luo YC; Lang ML; Cai WJ; Han ZY; Liu FY; Cheng ZG; Yu XL; Dou JP; Li X; Tan SL; Dong XJ; Liang P; Yu J
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):332-339. PubMed ID: 38733188
[No Abstract] [Full Text] [Related]
18. Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study.
Morinaga S; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Taniguchi Y; Asano Y; Nojima T; Tsuchiya H
BMC Cancer; 2024 May; 24(1):577. PubMed ID: 38730358
[TBL] [Abstract] [Full Text] [Related]
19. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
20. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract] [Full Text] [Related]
[Next]